Bridging Borders: How US-Asia Collaboration Is Redefining Global Biotech Deal-Making
June 24, 2026
30ABC
Type: Breakout Session
Focus Area:
Business Development and Investment
As the global biotech ecosystem becomes increasingly interconnected, in-licensing has evolved into a core growth engine, with US–Asia deal-making and NewCo formation continuing to accelerate as companies pursue capital-efficient paths to innovation and pipeline expansion.
This session brings together executives, investors, and dealmakers shaping the next wave of cross-border collaboration to explore how the right assets are identified, regional rights are structured, and incentives are aligned across scientific, regulatory, and commercial stakeholders. Panelists will examine valuation trends, due-diligence best practices, and evolving partnership and NewCo models that are reshaping how biotech’s scale globally.
Subtopic
Innovative Partnership Structures
Moderator
Speakers
EVP, Global Head of Cardiovascular, Renal and Metabolism Development
Novartis
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}